Cambridge-based therapeutics company Synlogic has secured $80 million in post IPO equity funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced June 12 and financed by Ginkgo Bioworks.
According to its Crunchbase profile, "Synlogic leverages the most advanced technology platform available for the creation of synthetically engineered, therapeutic microbes with the potential to make significant advancements in the treatment of disease."
The five-year-old company has raised four previous funding rounds, including a $42 million Series C round in 2017.
The round brings total funding raised by Cambridge companies in biotechnology over the past month to $91 million. The local biotechnology industry has seen 76 funding rounds over the past year, raking in a total of $3.6 billion in venture funding.
In other local funding news, life science company Kytopen announced a $3.6 million seed funding round on May 28.
According to Crunchbase, "Kytopen develops technology that modifies microorganisms."
The company also raised a seed round in 2017.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
